Themis Medicare Limited has informed the Exchange about Investor Presentation

TML/BSE/NSE/2025-26/07

20th May, 2025

The Manager Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code – 530199

Dear Sir/Madam,

The Manager – Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Symbol: THEMISMED

Subject: Investor Presentation

In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors’ Presentation of the Company, with respect to Business Overview of Themis Medicare Limited (‘the Company’).

Further, a copy of the same is also available on the website of the Company, viz., https://www.themismedicare.com

Kindly take the same on record and acknowledge receipt of the same.

Thanking you,

Yours faithfully,

For THEMIS MEDICARE LIMITED

Pradeep Chandan Director-Legal, Compliance & Company Secretary

Themis Medicare Limited Corporate Office: 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India *Tel.: 91-22-67607080*Fax: 91-22-67607070/ 28746621 Regd. Office: Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat CIN No.: L24110GJ1969PLC001590 *Tel/ Fax No.: Regd. Off.: 0260-2431447/ 2430219 *E-mail: themis@themismedicare.com*Website: www.themismedicare.com

In every possibility lies an innate, latent power to change lives

Themis Medicare Ltd.

Result Update Presentation Q4 & FY25

Disclaimer

This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

2

Table of Contents

Consolidated Financial Highlights

Company Overview

Way Ahead

3

Management Comment

Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said:

“In Q4FY25, we faced certain challenges through which we maneuvered successfully. The revenue for this quarter was impacted on account of a major and high-margin institutional business that performed well below our expectations, which had a bearing on the annual sales as well. Despite headwinds, we continued to move along our stated long-term strategic path of focusing on the formulation business by concentrating our energies on the critical segments.

Among our key businesses, the Hospital segment grew by over 11% in FY25. We shall keep up the momentum up by adding corporate hospitals (rate contracts) and in nursing homes increasing our portfolio to better our product offering.

FY25 was a significant year for the branded business which registered growth of 39% over previous year. As stated earlier, considerable investments have been made to develop capacity to grow this segment. We shall be working towards optimizing resource utilisation and expanding our reach. Also, we shall continue to concentrate on the focused brands and address tail brands separately.

Despite pricing challenges persisting in the API segment, this business witnessed sharp recovery in the Q4FY25 growing by more than 100% over Q3FY25. I am confident that this recovery is likely to continue in FY26.

In FY26, we shall focus on the strategy of Cost Optimization to achieve better operating efficiencies and also focus on improving the working capital requirements leading to better profitability with greater capital efficiency.

Now coming to consolidated financials, the revenue for full year FY25 stood at Rs. 405.52 crore growing by 6.22% over FY24. The gross margins grew by over 300 bps over last year to 67.45%. The EBITDA margin stood at 12.10% for FY25. The Formulation business grew by a very handsome 20% for the full year FY25. Consolidated EPS (for each share of face value of Re. 1) for FY25 is Rs. 3.24.”

4

Consolidated Financial Highlights

Consolidated Quarterly Financial Highlights

Revenue (Rs. Cr.)*

123.0

117.0

97.8

93.8

71.7

EBITDA (Rs. Cr.)** / Margin (%)

23.7%

29.2

9.5%

9.3

14.6%

17.1

9.1%

8.5

-8.1%

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

-5.8

PAT (Rs. Cr.) / Margin (%)

20.1%

24.7

12.2%

14.3

6.8%

6.6

0.6%

0.5

-13.5%

EPS (Rs.)

0.72

2.68

1.55

0.06

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q4FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

*Revenue consists of Other Operating Revenue **EBITDA is excl. Other Income

-9.7

-1.05

6

Consolidated Quarterly Financial Highlights – Q4 FY25

Particulars (Rs. Cr.)

Net Revenue Cost of Material Consumed Purchase of SIT Changes in Inventory Employee Expenses Other Expenses Total Expenditure EBITDA EBITDA Margin Other Income Depreciation Interest / Finance Cost

Add: Share of P/L of Associates & JV PBT Tax PAT PAT Margin% Basic EPS in Rs.

Q4 FY25 71.70 18.98 16.30 (14.68) 25.45 31.45 77.49 (5.78) (8.07%) 1.55 2.53 2.45

(1.91)

(11.13) (1.46) (9.66) (13.48%) (1.05)

Q4 FY24 97.82 21.65 11.79 5.78 22.46 26.83 88.52 9.30 9.50% 1.10 3.06 2.16

3.57

8.75 2.11 6.64 6.79% 0.72

Y-o-Y (%)

(27%)

(12%) (162%)

(245%)

(246%)

Q3 FY25 93.81 12.76 22.51 (6.77) 24.95 31.83 85.28 8.53 9.09% 1.02 2.54 2.79

(2.56)

1.66 1.14 0.52 0.55% 0.06

• Formulation Segment has grown

by 20.41% Y-o-Y for FY25

• Revenue from Hospital and Trade business has grown over 11% and ~39% respectively on Y-o-Y basis for FY25

• The API business witnessed a strong recovery in Q4FY25, with quarter-on-quarter a growth compared to Q3FY25.

115%

7

Consolidated Financial Highlights – FY25

Particulars (Rs. Cr.)

Net Revenue

Cost of Material Consumed

Purchase of SIT

Changes in Inventory

Employee Expenses

Other Expenses

Total Expenditure

EBITDA

EBITDA Margin

Other Income

Depreciation

Interest / Finance Cost

Add: Share of P/L of Associates & JV

PBT

Tax

PAT

PAT Margin%

EPS in Rs.

FY25

405.51

76.31

73.67

(17.98)

96.38

128.10

356.46

49.05

12.10%

4.67

9.93

10.04

5.93

39.67

9.84

29.83

7.36%

3.24

FY24

381.76

84.67

53.61

(1.57)

82.41

111.13

330.26

51.51

13.49%

4.76

12.25

9.38

18.81

53.44

9.92

43.52

11.40%

4.73

Y-o-Y (%)

6.22%

7.94%

(4.77%)

(25.76%)

(31.46%)

(31.50%)

8

Consolidated Balance Sheet as on 31st Mar’25

Rs. Cr.

Shareholders Funds

Share Capital

Other Equity

Non Controlling interest

Non Current Liabilities

Long Term Borrowing

Lease Liabilities

LT Provisions

Deferred Tax Liability(net)

Current Liabilities

Short term Borrowings

Lease Liabilities

Trade Payables

Total outstanding dues of micro and small

enterprises

Total outstanding dues of creditors other than micro and small enterprises

Other Financial Liabilities

Other Current Liabilities

Short term Provisions

Current Tax Liabilities (Net)

Total Equity & Liabilities

As on 31st Mar’25

402.60

9.20

393.39

(0.0014)

29.31

18.61

0

1.86

8.83

156.12

64.37

0.00

3.31

48.12

31.53

1.13

1.80

5.85

As on 31st Mar’24

377.67

9.20

368.46

0.00

35.77

26.77

0.00

1.60

7.39

152.98

69.02

0.00

3.08

44.21

27.40

0.89

0.96

7.42

588.03

566.42

Rs. Cr.

Non Current Assets

Plant, Property & Equipment

Capital Work In Progress

Right-of-use Assets

Intangible Assets

Investments

Financial Assets

Investments

Other Financial Assets

Deferred tax Assets (Net)

Other Non-Current Assets

Current Assets

Inventories

Financial Assets

Trade Receivables

Cash & Cash Equivalents

Bank balance other than above

Other Financial Assets

Other Current Assets

Total Assets

As on 31st Mar’25

As on 31st Mar’24

284.17

172.03

2.51

0.00

0.34

94.45

0.32

1.18

0.00

13.35

303.87

84.32

273.25

167.81

2.60

0.00

0.55

88.51

0.37

0.93

0.00

12.46

293.17

70.57

177.10

177.95

6.55

6.28

6.21

23.40

588.03

9.92

9.37

5.11

20.25

566.42

9

Company Overview

Snapshot of Company

Strategic focus To become Leader in Hospital Business in India with 4 growing divisions contributing 38.25% to revenue in FY24-25

3 State of art manufacturing facilities in India – 1 Formulations and 2 APIs (Synthetic + Biotech)

44+ Countries that we Export with Strong long- standing partnerships with global players for licensing (in & out).

Experienced professionals with proven

capabilities – 8 PhDs, 247 Masters and 1,509 Others

Strong Balance Sheet Total Debt to Equity at 0.21 in FY24-25

Rs. 1,353 Cr Market Cap (As on 31st March 2025)

12.10% EBITDA Margin (FY24-25)

Rs. 29.83 Cr PAT (FY24-25)

11

Strong Business Model

01

Hospital Business is major growth driver

03

Hospital Business

 Critical Care Division  Intensive Care Division  Institution Business  Exports

API Business

n

 API Legacy Business  New Product pipeline

supports hospital strategy and standalone global opportunities

n

02

Trade Business

n

 Pharma Division  Ortho Division  Gynecology Division  Strategy for growing through key brand focus in each division

Businesswise Revenue – Q4 FY25

API, Co. Mkt & Others 43%

Hospital 43%

Trade 14%

Businesswise Revenue – FY24-25

Hospital 38%

API, Co. Mkt & Others 42%

Trade 20%

Critical Care and Intensive Care teams contribute to building Hospital Business with new launches and increased hospitals/doctor’s coverage

12

Vertically Integrated State of Art Manufacturing Capabilities

Particulars

Location

Haridwar

Hyderabad

Vapi

Themis Medicare Ltd.

Artemis Biotech (Division of Themis Medicare Ltd.)

Themis Medicare Ltd.

Segment

Formulations

Synthetic APIs

Synthetic APIs

Capacity (per annum)

Tablets (Nos.) - 520 mn 9 mn Ointment (No. of Tubes) - 36 mn Ampoules (No. of Amp) - 12 mn Vials (No. of Vials) - 6 mn Pre-filled Syringes (Nos.)-

120 MT

Regulatory Approvals

EU GMP Certificate – Tablets & Gels

EU GMP

191 MT

GMP

Photos

13

Strong Research and Development Capabilities

Continued Investment in R&D (Rs. Cr.)

Business

API

Formulations

13.64

14.25

13.69

13.21

8.50

R&D

Analytical Lab Development

10

9

7

6

Product in a year with documentation

5 – 8

20-24

FY20-21

FY21-22

FY22-23

FY23-24

FY24-25

Products in work rolling

3 – 5

31

14

Way Ahead

Hospital Business Opportunity

n

Why Hospital Business Segment?  Growing market - Themis has strong foot in door through Critical

Care

 Market Highly Fragmented unlike West where 3-4 players control

90% market share

 Opportunities to grow segments within HB

High Entry Barriers  

Large Product Portfolio needed to service this segment Takes time to build relationship and reputation with key accounts

Opportunities Ahead  Focus on achieving Leadership position in India with Corporate Hospitals and Nursing Homes  With Expertise in Development of Complex Injectables - Company well placed to reap benefits

16

Our Aspirations

Strategy

 Focus on Hospital business  APIs to be developed - in-house consumption and commercial production

Growth

 CAGR of 35% over next 3 years  Maintain EBIDTA of over 25%

Vision & Position

 Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction

 Leadership in Anesthesia and Critical Care

New Target Markets

 Expansion in new RoW Markets in Phase I (0 to 3 years

- CIS, Latin America, GCC)

 Enter Regulated Markets in Phase II within 3 to 5 years

– EU, USA

17

Thank You

It takes one word

to change

the world “POSSIBILITY”

For further information, please contact:

Mr. Pradeep Chandan

Themis Medicare Ltd Email: pradeep.chandan@themismedicare.com Website: www.themismedicare.com

Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134

Adfactors PR Pvt Ltd Email: amit.sharma@adfactorspr.com / disha.shah@adfactorspr.com Website : www.adfactorspr.com

18